Developer docs
API playgroundTry for free, no card

Search company profiles

Regrow Biosciences

Full company profile

uuid000lodi

Namestring
Regrow Biosciences
Legal namestring
Regrow Biosciences Pvt Ltd
Websiteurl
regrow.in
Company typeenum
Private
Founded yearint
1989
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy products, regenerative medicine, stem cell banking, autologous biologics, orthopedic cell therapy
Industry5 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Blood and Organ Banks621991
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Medicine / Cell Therapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Cell Therapy Products (OSSGROW, CARTIGROW, XTIKTR)
TypeOne Time License
Description

Revenue from sale of patient-specific autologous cell therapy products. Each treatment is a one-time therapy where the patient's own cells are harvested, cultured, and reimplanted. Government purchases can be made through GeM (government e-marketplace). Products are covered by private and government insurance schemes. The company also offers franchise partnership for Biocell cord blood banking.

regrow.in
2Cord Blood Stem Cell Banking (Biocell)
TypeSubscription Recurring
Description

Premium umbilical cord blood banking service offered across 600 Indian cities. Revenue generated from cord blood banking subscription/preservation fees. Service includes the privilege to access cell therapy products including OSSGROW and CARTIGROW for hip and knee repair (REGROW health cover).

regrow.in
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details3 tiers
1CARTIGROW cartilage cell therapy - quote-based pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

All Regrow bills include transport and delivery kit charges. Regrow products are covered by all private and government insurance schemes. Government purchases available through GeM.

regrow.in
2OSSGROW bone cell therapy - quote-based pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

All Regrow bills include transport and delivery kit charges. Products are covered by private and government insurance. Government purchases available through GeM.

regrow.in
3Biocell cord blood banking - subscription model
ModelSubscriptionBilling cadenceAnnual
Notes

Cord blood banking service with REGROW health cover providing access to cell therapy for hip and knee repair.

regrow.in
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1OSSGROW®
Description

Patient-specific biological bone cell therapy for treatment of Avascular Necrosis (AVN). World's first bone cell therapy product.

regrow.in
+3 more records
Core offering1 text field

Regrow Biosciences manufactures patient-specific autologous cell therapy products—OSSGROW® (bone cell therapy for Avascular Necrosis), CARTIGROW® (cartilage cell therapy), and XTIKTR™ (epithelial cell therapy for urethral stricture)—produced by culturing the patient's own cells at a GMP facility in Lonavala, India. The company also operates BIOCELL®, a premium umbilical cord blood stem cell banking subscription service spanning 600+ Indian cities with attached future access to its cell therapy portfolio via REGROW health cover.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 1,000 patients have benefited through OSSGROW and CARTIGROW treatments
+5 more records
Product overview1 text field

Regrow Biosciences is a biotech company pioneering regenerative medicine through cell and stem cell-based products. The portfolio consists of four main offerings: OSSGROW® (world's first bone cell therapy for AVN with US FDA Orphan Drug Designation), CARTIGROW® (India's first cartilage cell therapy), XTIKTR™ (epithelial cell therapy for urethral stricture), and BIOCELL® (umbilical cord blood stem cell banking service). These products are underpinned by a proprietary three-pronged platform technology combining biological agents, biomechanical carriers, and delivery systems for targeted tissue repair. The company operates a GMP-compliant manufacturing facility at Lonavala, India, and maintains partnerships with over 340 doctors across 46 cities, having served more than 1,500 patients.

Product and service4 records
1OSSGROW®
CategoryRegenerative Medicine - Bone Cell Therapy
Description

OSSGROW® is a patient-specific, biological regenerative bone cell therapy that uses autologous adult live cultured osteoblasts derived from the patient's own bone marrow to treat Avascular Necrosis (AVN). The therapy involves extracting 4ml of bone marrow, culturing osteoblast cells for 14-21 days, and implanting 48 million cultured cells into the damaged femoral head to initiate new blood supply, remove dead bone, and form new bone tissue.

2CARTIGROW®
CategoryRegenerative Medicine - Cartilage Cell Therapy
Description

CARTIGROW® is a patient-specific, biological regenerative cartilage cell therapy that uses autologous chondrocyte implantation (ACI) to treat cartilage damage. The process involves arthroscopic extraction of healthy cartilage tissue, isolation and culture of chondrocyte cells for 2-3 weeks, and reimplantation of 48 million cultured chondrocytes onto the damaged joint area to regenerate hyaline cartilage.

3XTIKTR™
CategoryRegenerative Medicine - Epithelial Cell Therapy
Description

XTIKTR™ is a patient-specific, biological regenerative epithelial cell therapy that uses the patient's own cells to treat urethral stricture. Once epithelial cells are implanted, an epithelialization layer of new tissue is regenerated at the stricture site, relieving patient symptoms and restoring normal urine flow and sexual function.

4BIOCELL® Cord Blood Banking
CategoryStem Cell Banking Service
Description

BIOCELL® is India's leading premium umbilical cord blood stem cell banking service offering therapeutic solutions to treat more than 100 approved medical conditions. The service is available across 600 Indian cities and serves over 50,000 parents. It includes the Sibling Program for cord blood transplantation and bundled REGROW health cover providing access to OSSGROW and CARTIGROW therapies for hip and knee repair.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Regrow collaborated with DBT for the development of XTIKTR, the urology-based cell therapy product. XTIKTR was developed with DBT support and launched commercially in 2020. This collaboration with a government scientific body demonstrates regulatory credibility and co-development of novel cell therapy.

regrow.in
Strategic tierMinorTypeOthers
Description

Third-party payment processors handle payment collection for Regrow's services, adhering to PCI-DSS standards. Regrow does not store payment card details directly.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Athersys
TypeEmerging player
Description

Athersys is developing MultiStem®, an off-the-shelf cell therapy platform for indications including stroke and ARDS. Comparable as a regenerative medicine competitor advancing a cell therapy platform into multi-indication clinical development.

TypeRegional player
Description

Reliance Life Sciences operates an India-based stem cell and regenerative medicine business including cord blood banking (Reliance Cord Blood Bank) and cell therapy R&D — directly comparable to Regrow's Biocell cord blood banking and cell therapy portfolio within the same geography and customer base.

3TiGenix (Takeda)
TypeBroad incumbent
Description

TiGenix pioneered the first EMA-approved autologous chondrocyte cell therapy (ChondroCelect) before being acquired by Takeda. It is the most established global benchmark for cartilage cell therapy commercialization and now competes from within a large-incumbent pharma portfolio.

TypeRegional player
Description

Pharmicell (Korea) develops and commercializes stem cell-based products including heart cell and cartilage therapies. Comparable as a regional autologous/cell therapy specialist with similar indications and commercial-stage maturity outside Regrow's home market.

TypeDirect peer
Description

Bangalore-based Stempeutics develops stem cell-based therapies (Stempeucel®) targeting critical limb ischemia and other indications with DCGI-aligned regulatory pathways — a domestic India peer operating in the same autologous/allogeneic cell therapy category.

TypeDirect peer
Description

LifeCell is one of India's largest private cord blood and stem cell banking operators serving expectant parents — a head-to-head Biocell® competitor on the consumer banking side of Regrow's business model.

TypeBroad incumbent
Description

Mesoblast develops allogeneic cell-based medicines across inflammatory and cardiovascular indications. It is a broadly comparable regenerative medicine incumbent with FDA pathway experience that contrasts with Regrow's autologous approach.

TypeDirect peer
Description

Vericel develops and commercializes autologous cell therapies, most notably MACI (autologous cultured chondrocytes on a porcine collagen membrane) for cartilage repair — directly comparable to Regrow's CARTIGROW® ACI platform in product modality, indication, and target surgical customers.

TypeDirect peer
Description

Cryoviva operates pan-India umbilical cord blood and stem cell banking services to expectant parents — a direct Biocell® competitor in pricing, distribution, and geography.

TypeDirect peer
Description

J-TEC commercializes autologous cell therapies including cultured epidermal autografts (JACE) and autologous cartilage (JACC) — directly comparable business model to Regrow's curated autologous orthopedic and epithelial cell therapy products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regrow Biosciences

Regenerative Medicine / Cell Therapyregrow.in

Regrow Biosciences firmographics

Firmographics
Name
Regrow Biosciences
Legal name
Regrow Biosciences Pvt Ltd
Website
https://regrow.in
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Regrow Biosciences industry classification

Industry
Product category
Regenerative Medicine / Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • Cell therapy products
  • Regenerative medicine
  • Stem cell banking
  • Autologous biologics
  • Orthopedic cell therapy

Where Regrow Biosciences is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Regrow Biosciences business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Cell Therapy Products (OSSGROW, CARTIGROW, XTIKTR): Revenue from sale of patient-specific autologous cell therapy products. Each treatment is a one-time therapy where the patient's own cells are harvested, cultured, and reimplanted. Government purchases can be made through GeM (government e-marketplace). Products are covered by private and government insurance schemes. The company also offers franchise partnership for Biocell cord blood banking.
  2. Cord Blood Stem Cell Banking (Biocell): Premium umbilical cord blood banking service offered across 600 Indian cities. Revenue generated from cord blood banking subscription/preservation fees. Service includes the privilege to access cell therapy products including OSSGROW and CARTIGROW for hip and knee repair (REGROW health cover).

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCARTIGROW cartilage cell therapy - quote-based pricing
One time/ perpetual licensePay-as-you-goOSSGROW bone cell therapy - quote-based pricing
SubscriptionAnnualBiocell cord blood banking - subscription model

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Regrow Biosciences product offering

Product offering

Core offering

Regrow Biosciences manufactures patient-specific autologous cell therapy products—OSSGROW® (bone cell therapy for Avascular Necrosis), CARTIGROW® (cartilage cell therapy), and XTIKTR™ (epithelial cell therapy for urethral stricture)—produced by culturing the patient's own cells at a GMP facility in Lonavala, India. The company also operates BIOCELL®, a premium umbilical cord blood stem cell banking subscription service spanning 600+ Indian cities with attached future access to its cell therapy portfolio via REGROW health cover.

Product overview

Regrow Biosciences is a biotech company pioneering regenerative medicine through cell and stem cell-based products. The portfolio consists of four main offerings: OSSGROW® (world's first bone cell therapy for AVN with US FDA Orphan Drug Designation), CARTIGROW® (India's first cartilage cell therapy), XTIKTR™ (epithelial cell therapy for urethral stricture), and BIOCELL® (umbilical cord blood stem cell banking service). These products are underpinned by a proprietary three-pronged platform technology combining biological agents, biomechanical carriers, and delivery systems for targeted tissue repair. The company operates a GMP-compliant manufacturing facility at Lonavala, India, and maintains partnerships with over 340 doctors across 46 cities, having served more than 1,500 patients.

Differentiator

Problem solved

Functional benefit

Brands

  • OSSGROW®: Patient-specific biological bone cell therapy for treatment of Avascular Necrosis (AVN). World's first bone cell therapy product.
  • CARTIGROW®
  • XTIKTR™
  • BIOCELL®

Products and services

  • OSSGROW® OSSGROW® is a patient-specific, biological regenerative bone cell therapy that uses autologous adult live cultured osteoblasts derived from the patient's own bone marrow to treat Avascular Necrosis (AVN). The therapy involves extracting 4ml of bone marrow, culturing osteoblast cells for 14-21 days, and implanting 48 million cultured cells into the damaged femoral head to initiate new blood supply, remove dead bone, and form new bone tissue.
  • CARTIGROW® CARTIGROW® is a patient-specific, biological regenerative cartilage cell therapy that uses autologous chondrocyte implantation (ACI) to treat cartilage damage. The process involves arthroscopic extraction of healthy cartilage tissue, isolation and culture of chondrocyte cells for 2-3 weeks, and reimplantation of 48 million cultured chondrocytes onto the damaged joint area to regenerate hyaline cartilage.
  • XTIKTR™ XTIKTR™ is a patient-specific, biological regenerative epithelial cell therapy that uses the patient's own cells to treat urethral stricture. Once epithelial cells are implanted, an epithelialization layer of new tissue is regenerated at the stricture site, relieving patient symptoms and restoring normal urine flow and sexual function.
  • BIOCELL® Cord Blood Banking BIOCELL® is India's leading premium umbilical cord blood stem cell banking service offering therapeutic solutions to treat more than 100 approved medical conditions. The service is available across 600 Indian cities and serves over 50,000 parents. It includes the Sibling Program for cord blood transplantation and bundled REGROW health cover providing access to OSSGROW and CARTIGROW therapies for hip and knee repair.

Quantifiable outcome

  • Over 1,000 patients have benefited through OSSGROW and CARTIGROW treatments
  • +5 more outcomes

Companies that use Regrow Biosciences

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Regrow Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Regrow Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Department of Biotechnology (DBT), Ministry of Science and Technology, Government of IndiacoreStrategic or Co-development PartnerRegrow collaborated with DBT for the development of XTIKTR, the urology-based cell therapy product. XTIKTR was developed with DBT support and launched commercially in 2020. This collaboration with a government scientific body demonstrates regulatory credibility and co-development of novel cell therapy.
  • Third-Party Payment ProcessorsminorOthersThird-party payment processors handle payment collection for Regrow's services, adhering to PCI-DSS standards. Regrow does not store payment card details directly.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Regrow Biosciences competitors and assessment

Company assessment

Emerging players

  • Athersys: Athersys is developing MultiStem®, an off-the-shelf cell therapy platform for indications including stroke and ARDS. Comparable as a regenerative medicine competitor advancing a cell therapy platform into multi-indication clinical development.

Regional players

  • Reliance Life Sciences: Reliance Life Sciences operates an India-based stem cell and regenerative medicine business including cord blood banking (Reliance Cord Blood Bank) and cell therapy R&D — directly comparable to Regrow's Biocell cord blood banking and cell therapy portfolio within the same geography and customer base.
  • Pharmicell: Pharmicell (Korea) develops and commercializes stem cell-based products including heart cell and cartilage therapies. Comparable as a regional autologous/cell therapy specialist with similar indications and commercial-stage maturity outside Regrow's home market.

Broad incumbents

  • TiGenix (Takeda): TiGenix pioneered the first EMA-approved autologous chondrocyte cell therapy (ChondroCelect) before being acquired by Takeda. It is the most established global benchmark for cartilage cell therapy commercialization and now competes from within a large-incumbent pharma portfolio.
  • Mesoblast: Mesoblast develops allogeneic cell-based medicines across inflammatory and cardiovascular indications. It is a broadly comparable regenerative medicine incumbent with FDA pathway experience that contrasts with Regrow's autologous approach.

Direct peers

  • Stempeutics Research: Bangalore-based Stempeutics develops stem cell-based therapies (Stempeucel®) targeting critical limb ischemia and other indications with DCGI-aligned regulatory pathways — a domestic India peer operating in the same autologous/allogeneic cell therapy category.
  • LifeCell International: LifeCell is one of India's largest private cord blood and stem cell banking operators serving expectant parents — a head-to-head Biocell® competitor on the consumer banking side of Regrow's business model.
  • Vericel Corporation: Vericel develops and commercializes autologous cell therapies, most notably MACI (autologous cultured chondrocytes on a porcine collagen membrane) for cartilage repair — directly comparable to Regrow's CARTIGROW® ACI platform in product modality, indication, and target surgical customers.
  • Cryoviva (Cryobank India): Cryoviva operates pan-India umbilical cord blood and stem cell banking services to expectant parents — a direct Biocell® competitor in pricing, distribution, and geography.
  • Japan Tissue Engineering (J-TEC, FUJIFILM): J-TEC commercializes autologous cell therapies including cultured epidermal autografts (JACE) and autologous cartilage (JACC) — directly comparable business model to Regrow's curated autologous orthopedic and epithelial cell therapy products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Regrow Biosciences social profiles

Digital presence

Regrow Biosciences compliance and trust

Trust signal

Compliance4 records

Regrow Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regrow Biosciences leadership team

Management profile

Number of profiles

Profiles7 records

Regrow Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regrow Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regrow Biosciences

What does Regrow Biosciences do?

Regrow Biosciences manufactures patient-specific autologous cell therapy products—OSSGROW® (bone cell therapy for Avascular Necrosis), CARTIGROW® (cartilage cell therapy), and XTIKTR™ (epithelial cell therapy for urethral stricture)—produced by culturing the patient's own cells at a GMP facility in Lonavala, India. The company also operates BIOCELL®, a premium umbilical cord blood stem cell banking subscription service spanning 600+ Indian cities with attached future access to its cell therapy portfolio via REGROW health cover.

Is Regrow Biosciences a public or private company?

Regrow Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Regrow Biosciences founded?

Regrow Biosciences was founded in 1989. It employs 101 to 250 people.

Where is Regrow Biosciences based?

Regrow Biosciences is headquartered in Mumbai, India, in the Asia region.

How does Regrow Biosciences make money?

Two revenue lines are on record. Cell Therapy Products (OSSGROW, CARTIGROW, XTIKTR) is the primary driver. The others are cord Blood Stem Cell Banking (Biocell).

Who are Regrow Biosciences's main competitors?

Athersys is listed as an emerging player. Regional players are Reliance Life Sciences and Pharmicell. Broad incumbents are TiGenix (Takeda) and Mesoblast. Direct peers are Stempeutics Research, LifeCell International, Vericel Corporation, Cryoviva (Cryobank India) and Japan Tissue Engineering (J-TEC, FUJIFILM).

Does Regrow Biosciences have an API?

No public API is recorded for Regrow Biosciences.

What industry is Regrow Biosciences in?

Regrow Biosciences's product category is Regenerative Medicine / Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales